(Q37134412)

18 August 2017

1 reference

title

Gemcitabine in the treatment of metastatic pancreatic cancer (English)

1 reference

18 August 2017

1 reference

Andreas Hilbig

1

1 reference

18 August 2017

Helmut Oettle

series ordinal

2

1 reference

18 August 2017

publication date

1 April 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

published in

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

511-523

1 reference

Apoptosis: targets in pancreatic cancer

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II study of gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Changing the way we think about chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

An early phase II study of S-1 in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Toward a glioblastoma vaccine: promise and potential pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Women's interest in gene expression analysis for breast cancer recurrence risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Growth factors and their receptors in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Pathways for aberrant angiogenesis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Prognostic significance of angiogenesis in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Dominant negative MEKK1 inhibits survival of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

siRNA therapeutics: big potential from small RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

The hypoxic inducible stress response as a target for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Development of the PANVAC-VF vaccine for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

Site of oncologic specialty care for older adolescents in Utah.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.4.511

21 January 2018

Identifiers

DOI

10.1586/14737140.8.4.511

1 reference

release_p6f2fkac7ngihnahqljap2todu

18 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p6f2fkac7ngihnahqljap2todu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference